CoChat
Sign Up
Cited by 138Fatty Acid Research and HealthAquaculture Nutrition and GrowthNutritional Studies and Diet

Role of n-3 long-chain polyunsaturated fatty acids in human nutrition and health: Review of recent studies and recommendations

Open access
Van Dael, Peter·2021·Nutrition Research and Practice
DOI 10.4162/nrp.2021.15.2.137PMC PMC8007408
Open this paper in CoChat — free account

Abstract

Long-chain (LC) n-3 polyunsaturated fatty acids (n-3 PUFAs), in particular docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), are nutrients involved in many metabolic and physiological processes, and are referred to as n-3 LCPUFA. They have been extensively studied for their effects in human nutrition and health. This paper provides an overview on metabolism, sources, dietary intake, and status of n-3 LCPUFA. A summary of the dietary recommendations for n-3 LCPUFAs for different age groups as well as specific physiological conditions is provided. Evidence for n-3 LCPUFA in cardiovascular diseases, including new studies, is reviewed. Expert recommendations generally support a beneficial effect of n-3 LCPUFA on cardiovascular health and recommend a daily intake of 500 mg as DHA and EPA, or 1-2 servings of fish per week. The role of n-3 LCPUFA on brain health, in particular neurodegenerative disorders and depression, is reviewed. The evidence for beneficial effects of n-3 LCPUFA on neurodegenerative disorders is non-conclusive despite mechanistic support and observational data. Hence, no definite n-3 LCPUFA expert recommendations are made. Data for the beneficial effect of n-3 LCPUFA on depression are generally compelling. Expert recommendations have been established: 200-300 mg/day for depression; up to 1-2 g/day for major depressive disorder. Recent studies support a beneficial role of n-3 LCPUFAs in reducing the risk for premature birth, with a daily intake of 600-800 mg of DHA during pregnancy. Finally, international experts recently reviewed the scientific evidence on DHA and arachidonic acid (ARA) in infant nutrition and concluded that the totality of data support that infant and follow-on formulas should provide both DHA and ARA at levels similar to those in breast milk. In conclusion, the available scientific data support that dietary recommendations for n-3 LCPUFA should be established for the general population and for subjects with specific physiological conditions.

AI snapshot

Written from the paper’s full text.

TL;DR

This review summarizes n-3 LCPUFA metabolism, sources, intake/status, and expert recommendations, focusing on cardiovascular disease, brain health, pregnancy, and infant nutrition. It concludes that dietary recommendations are supported for the general population and specific physiological conditions, while evidence for neurodegenerative disorders remains non-conclusive.

Key findings

  • Cardiovascular expert recommendations generally support benefit and recommend a daily intake of 500 mg DHA + EPA, or 1–2 servings of fish per week; EFSA set an adequate intake of 250 mg/day EPA + DHA for adults. In VITAL, the primary outcome was not statistically significant but showed an 8% reduction in major cardiovascular events, 28% lower total myocardial infarction, and 50% lower fatal myocardial infarction; REDUCE-IT reported that 4 g/day EPA reduced first major adverse cardiovascular events by 25% and cardiovascular death by 20%.
  • For brain health, evidence for neurodegenerative disorders is non-conclusive and no definite expert n-3 LCPUFA recommendations are made; depression evidence is generally compelling, with ANSES recommending 200–300 mg/day and MDD guidelines recommending 1–2 g/day net EPA. A 2019 meta-analysis of 26 studies and 2,160 participants found an overall beneficial effect on depression symptoms, with EPA-pure and EPA-major formulations at ≤ 1 g/day showing clinical benefits.
  • During pregnancy, recent studies support 600–800 mg/day DHA to reduce premature birth risk; one trial with 800 mg/day DHA reported early-preterm birth at 1.09% vs. 2.25% (P = 0.03), and another with 600 mg/day DHA reported longer gestation by 2.9 days and greater birth weight by 172 g. International experts concluded infant and follow-on formulas should provide both DHA and ARA at levels similar to breast milk.
  • Globally, less than 20% of the world’s population consume ≥ 250 mg/day of seafood-origin n-3 LCPUFA; blood EPA + DHA levels were very low (≤ 4%) in North, Central, and South America, Europe, the Middle East, Southeast Asia, and Africa, and high (> 8%) in countries adjacent to the Sea of Japan, Scandinavia, and some indigenous or non-Westernized populations.

Methods

  • Narrative review; no primary data collection. It provides an overview of n-3 LCPUFA metabolism, dietary sources, intake and status, and expert recommendations, then reviews recent evidence in CVD, brain health, pregnancy/prematurity, and infant nutrition.
  • Evidence base includes expert reports (FAO/WHO, EFSA, IOM, NHMRC, ANSES, AHA), randomized trials (e.g., VITAL, REDUCE-IT, pregnancy DHA trials), observational studies, systematic reviews, and meta-analyses.
  • Main analysis is qualitative synthesis and interpretation of cited literature; no systematic search strategy or quantitative pooling is described.

Limitations

  • Stated in the paper: EPA and DHA intake estimates are limited by food composition databases and dietary reporting errors; neurodegenerative evidence is non-conclusive; clinical trials are less conclusive than observational studies; no tolerable upper intake level for n-3 LCPUFA could be established due to insufficient data; not all reviews support a beneficial role in cardiovascular health, with heterogeneity among populations, n-3 status, and intake discrepancies.
  • Evident from the text: as a narrative review, it lacks a described systematic search, inclusion criteria, risk-of-bias assessment, or meta-analytic synthesis, so conclusions depend on the selected cited studies and expert interpretations.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.4162/nrp.2021.15.2.137

Cites

128 of 128 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Claims the paper makes

0 of 118 cited sources checked · 0 supported · 0 flagged

  • Premisecitation

    Dietary n-3 LCPUFA EPA and DHA have been associated with a decreased risk of chronic diseases, in particular CVD and cognitive decline.

    “Dietary n-3 LCPUFA, eicosapentaenoic acid (EPA, 20:5n-3), and docosahexaenoic acid (DHA, 22:6n-3), have been associated with a decreased risk of chronic diseases, in particular CVD [3] and cognitive decline [4].”
    Quote in the paperSubstantial claim0 of 2 sources checked
    • cites [3] Mozaffarian, 2011, J Am Coll Cardiol source

      Not checked in the free run.

    • cites [4] Sinn, 2012, Br J Nutr source

      Not checked in the free run.

  • Interpretationreasoning

    The evidence for beneficial effects of n-3 LCPUFA on neurodegenerative disorders is non-conclusive despite mechanistic support and observational data.

    “The evidence for beneficial effects of n-3 LCPUFA on neurodegenerative disorders is non-conclusive despite mechanistic support and observational data.”
    Quote in the paperSubstantial claim
  • Premisecitation

    Geographical regions with high EPA + DHA blood levels (> 8%) included countries adjacent to the Sea of Japan, Scandinavia, and areas with indigenous populations or populations not fully adapted to Westernized food habits.

    “Data revealed that geographical regions with high EPA + DHA blood levels (> 8%) included countries adjacent to the Sea of Japan, Scandinavia, and areas with indigenous populations or populations not fully adapted to Westernized food habits.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [25] Stark, 2016, Prog Lipid Res source

      Not checked in the free run.

  • Interpretationnone given

    Data for the beneficial effect of n-3 LCPUFA on depression are generally compelling.

    “Data for the beneficial effect of n-3 LCPUFA on depression are generally compelling.”
    Quote in the paperNot a substantial claim
  • Interpretationnone given

    Most currently available data are overall supportive of n-3 LCPUFA reducing the risk of cardiac disease or death.

    “As most currently available data are overall supportive of n-3 LCPUFA reducing the risk of cardiac disease or death, expert guidelines have converged toward the development of consistent recommendations for the general population to consume at least 250 mg/day of n-3 LCPUFA or at least 2 servings/week of oily fish [262730313238].”
    Quote in the paperSubstantial claim
  • May combine two claims. 47
  • Classified as probably not a substantial claim. 35

  • May combine two claims.

    Premisecitation

    Blood levels of n-3 LCPUFA, particularly EPA and DHA, have been linked to a reduced risk of primary cardiac arrest, sudden cardiac death, and all cause dementia.

    “Blood levels of n-3 LCPUFA, particularly EPA and DHA, have been linked to a reduced risk of primary cardiac arrest [22], sudden cardiac death [23], and all cause dementia [24].”
    Quote in the paperNot a substantial claim0 of 3 sources checked
    • cites [22] Siscovick, 1995, JAMA source

      Not checked in the free run.

    • cites [23] Albert, 2002, N Engl J Med source

      Not checked in the free run.

    • cites [24] Schaefer, 2006, Arch Neurol source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Estimates for the conversion of ALA into EPA range from 8% to 12%, while its conversion into DHA may be less than 1%.

    “Estimates for the conversion of ALA into EPA range from 8% to 12%, while its conversion into DHA may be less than 1% [8].”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [8] Goyens, 2006, Am J Clin Nutr source

      Not checked in the free run.

  • May combine two claims.

    Interpretationreasoning

    Polymorphisms in the FADS genes determine the efficiency of endogenous PUFA processing, and nutritional and functional responses are likely to vary depending on the FADS genotype present.

    “Polymorphisms in the FADS genes determine the efficiency of endogenous PUFA processing, and, therefore, nutritional and functional responses are likely to vary depending on the FADS genotype present.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Premisecitation

    Dietary intake of n-3 LCPUFA is largely dependent on dietary habits and shows considerable geographical and population differences.

    “The dietary intake of n-3 LCPUFA is largely dependent on dietary habits and hence has been reported to show considerable geographical and population differences [13].”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [13] Micha, 2014, BMJ source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    The ability to convert ALA into n-3 LCPUFA and the levels of n-3 LCPUFA in plasma phospholipids and red blood cells are individually related to polymorphisms in the human Δ-5 and Δ-6 desaturase genes FADS1 and FADS2.

    “The ability to convert ALA into n-3 LCPUFA and the levels of n-3 LCPUFA in plasma phospholipids and red blood cells are, moreover, individually related to polymorphisms in the human Δ-5 and Δ-6 desaturase genes fatty acid desaturase 1 and 2 (FADS1 and FADS2, respectively) [12].”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [12] Schaeffer, 2006, Hum Mol Genet source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S4 (based). May combine two claims.

    Premisenone given

    Expert recommendations for depression are 200-300 mg/day, and up to 1-2 g/day for major depressive disorder.

    “Expert recommendations have been established: 200–300 mg/day for depression; up to 1–2 g/day for major depressive disorder.”
    Quote in the paperNot a substantial claim

  • Classified as probably not a substantial claim.

    Interpretationnone given

    There is no consistent, global recommendation for dietary intake of n-3 LCPUFA to manage nutritional needs and reduce NCD risk.

    “Despite overall positive data on a beneficial role of n-3 LCPUFA in human health, there is no consistent, global recommendation for dietary intake of n-3 LCPUFA to manage nutritional needs and reduce NCD risk.”
    Quote in the paperSubstantial claim

  • Classified as probably not a substantial claim.

    Interpretationnone given

    International experts concluded that the totality of data support that infant and follow-on formulas should provide both DHA and ARA at levels similar to those in breast milk.

    “International experts recently reviewed the scientific evidence on DHA and arachidonic acid (ARA) in infant nutrition and concluded that the totality of data support that infant and follow-on formulas should provide both DHA and ARA at levels similar to those in breast milk.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Premisenone given

    Recent studies support a beneficial role of n-3 LCPUFAs in reducing the risk for premature birth, with a daily intake of 600-800 mg of DHA during pregnancy.

    “Recent studies support a beneficial role of n-3 LCPUFAs in reducing the risk for premature birth, with a daily intake of 600–800 mg of DHA during pregnancy.”
    Quote in the paperNot a substantial claim

  • Classified as probably not a substantial claim. May combine two claims.

    Interpretationreasoning

    The available scientific data support that dietary recommendations for n-3 LCPUFA should be established for the general population and for subjects with specific physiological conditions.

    “In conclusion, the available scientific data support that dietary recommendations for n-3 LCPUFA should be established for the general population and for subjects with specific physiological conditions.”
    Quote in the paperSubstantial claim

  • Classified as probably not a substantial claim. May combine two claims.

    Interpretationnone given

    Expert recommendations generally support a beneficial effect of n-3 LCPUFA on cardiovascular health and recommend a daily intake of 500 mg as DHA and EPA, or 1-2 servings of fish per week.

    “Expert recommendations generally support a beneficial effect of n-3 LCPUFA on cardiovascular health and recommend a daily intake of 500 mg as DHA and EPA, or 1–2 servings of fish per week.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    During pregnancy and lactation, NHMRC recognized increased needs for n-3 LCPUFA intake and estimated that 115 mg and 145 mg per day, respectively, would cover those needs.

    “During pregnancy and lactation, NHMRC recognized increased needs for n-3 LCPUFA intake and estimated that 115 mg and 145 mg per day, respectively, would cover those needs.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [34] National Health and Medical Research Council (AU), 2017

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Globally, there is considerable variability in EPA + DHA blood levels, and the very low to low range of blood EPA + DHA levels for most regions of the world may increase global risk for chronic disease.

    “The authors concluded that, globally, there is considerable variability in EPA + DHA blood levels, and that the very low to low range of blood EPA + DHA levels for most regions of the world may increase global risk for chronic disease.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [25] Stark, 2016, Prog Lipid Res source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    The combined EPA+DHA+DPA adequate intakes per day were set at 40 mg (1-3 years), 50 mg (4-8 years), 70 mg (9-13 years/boys), 85 mg (9-13 years/girls), 125 mg (14-18 years/boys), 85 mg (14-18 years/girls), 160 mg (men), and 90 mg (women).

    “The combined EPA+DHA+DPA adequate intakes per day were set at 40 mg (1–3 years), 50 mg (4–8 years), 70 mg (9–13 years/boys), 85 mg (9–13 years/girls), 125 mg (14–18 years/boys), 85 mg (14–18 years/girls), 160 mg (men), and 90 mg (women).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [34] National Health and Medical Research Council (AU), 2017

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    For pregnant and lactating women, the ANSES recommendations were 250 mg of DHA or 500 mg of combined DHA and EPA.

    “For pregnant and lactating women, the ANSES recommendations were 250 mg of DHA or 500 mg of combined DHA and EPA.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [38] French Agency for Food, Environmental and Occupational Health Safety (ANSES). Update of the Recommended Nutritional Intake for Fatty Acids. Collective Expert Report [Internet]. Maisons-Alfort. ANSES. 2011. cited 2020 April 5. Available from: https://www.anses.fr/en/system/files/NUT2006sa0359Ra.pdf

      Not checked in the free run.

  • Classified as probably not a substantial claim.

    Premisereasoning

    Rounding up to the nearest 10 mg, this established a level of 610 mg/day for men and 430 mg/day for women.

    “Rounding up to the nearest 10 mg, this established a level of 610 mg/day for men and 430 mg/day for women.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [34] National Health and Medical Research Council (AU), 2017

      Not checked in the free run.

  • Classified as probably not a substantial claim.

    Premisecitation

    For pregnancy and lactation, a daily intake of 100-200 mg of DHA, in addition to the adult adequate intake, was established to meet the increased demand for n-3 LCPUFA.

    “For pregnancy and lactation, a daily intake of 100–200 mg of DHA, in addition to the adult adequate intake, was established to meet the increased demand for n-3 LCPUFA.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [27] EFSA Panel on Dietetic Products, Nutrition, and Allergies (NDA), 2010, EFSA J

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    The 2015-2020 Dietary Guidelines for Americans and the Scientific Report of the 2015 US Dietary Guidelines Advisory Committee have recommended at least 2 servings of fish per week, providing an average of 250 mg EPA plus DHA per day, in place of other animal sources of protein.

    “The 2015–2020 Dietary Guidelines for Americans and the Scientific Report of the 2015 US Dietary Guidelines Advisory Committee have recommended at least 2 servings of fish per week, providing an average of 250 mg EPA plus DHA per day, in place of other animal sources of protein [3233].”
    Quote in the paperNot a substantial claim0 of 2 sources checked
    • cites [32] U.S. Department of Health and Human Services, 2015

      Not checked in the free run.

    • cites [33] US Department of Agriculture, 2015

      Not checked in the free run.

  • Classified as probably not a substantial claim.

    Premisecitation

    For CVD risk reduction in the general population, ANSES recommends a daily intake of 500 mg of combined EPA and DHA.

    “Similarly, for CVD risk reduction in the general population, ANSES recommends a daily intake of 500 mg of combined EPA and DHA.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [38] French Agency for Food, Environmental and Occupational Health Safety (ANSES). Update of the Recommended Nutritional Intake for Fatty Acids. Collective Expert Report [Internet]. Maisons-Alfort. ANSES. 2011. cited 2020 April 5. Available from: https://www.anses.fr/en/system/files/NUT2006sa0359Ra.pdf

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    The FDA recommends not exceeding 3 g/day EPA and DHA combined, with an intake of up to 2 g/day from dietary supplements.

    “Based on the totality of evidence, the FDA recommends not exceeding 3 g/day EPA and DHA combined, with an intake of up to 2 g/day from dietary supplements [31].”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [31] U.S. Food and Drug Administration (FDA). Qualified Health Claims: Letters of Enforcement Discretion [Internet]. Silver Spring. FDA. 2020. cited 2020 April 5. Available from: https://www.fda.gov/food/food-labeling-nutrition/qualified-health-claims-letters-enforcement-discretion

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    The IOM did not establish specific intake recommendations for EPA, DHA, or other n-3 LCPUFA, but it did recommend that approximately 10% of the Acceptable Macronutrient Distribution Range for ALA can be consumed as EPA and/or DHA.

    “The IOM did not establish specific intake recommendations for EPA, DHA, or other n-3 LCPUFA, but it did recommend that approximately 10% of the Acceptable Macronutrient Distribution Range for ALA can be consumed as EPA and/or DHA.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [29] Institute of Medicine (US), 2005

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    The NHMRC stated that, based on the concept of essentiality and given the lack of dose-response data, adequate intakes could be established for LA (n-6 in infants), ALA, and the combined n-3 LCPUFA, DHA + EPA + DPA, by using median population intakes in Australia.

    “The NHMRC stated that, based on the concept of essentiality and given the lack of dose-response data, adequate intakes could be established for LA (n-6 in infants), ALA, and the combined n-3 LCPUFA, DHA + EPA + DPA, by using median population intakes in Australia.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [34] National Health and Medical Research Council (AU), 2017

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisereasoning

    The French Food Safety Authority (ANSES) recommended a daily intake of 250 mg of DHA to meet adult nutritional requirements, which is twice the recommendation established in 2001.

    “Based on the low conversion of ALA into DHA, the ANSES recommended a daily intake of 250 mg of DHA to meet adult nutritional requirements, which is twice the recommendation established in 2001 [39].”
    Quote in the paperNot a substantial claim0 of 2 sources checked
    • cites [38] French Agency for Food, Environmental and Occupational Health Safety (ANSES). Update of the Recommended Nutritional Intake for Fatty Acids. Collective Expert Report [Internet]. Maisons-Alfort. ANSES. 2011. cited 2020 April 5. Available from: https://www.anses.fr/en/system/files/NUT2006sa0359Ra.pdf

      Not checked in the free run.

    • cites [39] Beaufrère, 2001

      Not checked in the free run.

  • Classified as probably not a substantial claim.

    Premisecitation

    This recommendation is increased up to 750 mg/day for subjects with increased cardiovascular risk profiles.

    “However, this recommendation is increased up to 750 mg/day for subjects with increased cardiovascular risk profiles.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [38] French Agency for Food, Environmental and Occupational Health Safety (ANSES). Update of the Recommended Nutritional Intake for Fatty Acids. Collective Expert Report [Internet]. Maisons-Alfort. ANSES. 2011. cited 2020 April 5. Available from: https://www.anses.fr/en/system/files/NUT2006sa0359Ra.pdf

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    The EFSA set an adequate intake level for ALA at 0.5% of energy and did not identify an upper safe level.

    “The EFSA set an adequate intake level for ALA at 0.5% of energy and did not identify a upper safe level.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [27] EFSA Panel on Dietetic Products, Nutrition, and Allergies (NDA), 2010, EFSA J

      Not checked in the free run.

  • Classified as probably not a substantial claim. May combine two claims.

    Premisecitation

    For adult males and non-pregnant/non-lactating adult females, 0.25 g/day of EPA plus DHA is recommended, given there is insufficient evidence to establish a specific minimum intake for either EPA or DHA alone.

    “For adult males and non-pregnant/non-lactating adult females, 0.25 g/day of EPA plus DHA is recommended, given there is insufficient evidence to establish a specific minimum intake for either EPA or DHA alone.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [26] Food and Agriculture Organization of the United Nations, 2010

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    ANSES recommended for adults 500 mg of combined DHA and EPA.

    “Similarly, and after considering data regarding risk reduction related to n-3 LCPUFA consumption, a recommendation for adults was established at 500 mg of combined DHA and EPA.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [38] French Agency for Food, Environmental and Occupational Health Safety (ANSES). Update of the Recommended Nutritional Intake for Fatty Acids. Collective Expert Report [Internet]. Maisons-Alfort. ANSES. 2011. cited 2020 April 5. Available from: https://www.anses.fr/en/system/files/NUT2006sa0359Ra.pdf

      Not checked in the free run.

  • Classified as probably not a substantial claim.

    Premisecitation

    The FAO/WHO 2010 expert consultation concluded that a daily ALA intake of 0.5-0.6% of energy is required to cover nutritional needs.

    “The expert consultation concluded that a daily ALA intake of 0.5–0.6% of energy is required to cover nutritional needs.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [26] Food and Agriculture Organization of the United Nations, 2010

      Not checked in the free run.

  • Classified as probably not a substantial claim.

    Premisecitation

    ANSES concluded that it was sufficient to establish a minimum daily intake recommendation for the risk reduction of psychiatric diseases, in particular depression (200-300 mg of DHA + EPA).

    “With regard to the management of NCDs, ANSES reviewed the available evidence and concluded that it was sufficient to establish a minimum daily intake recommendation for the risk reduction of psychiatric diseases, in particular depression (200–300 mg of DHA + EPA).”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [38] French Agency for Food, Environmental and Occupational Health Safety (ANSES). Update of the Recommended Nutritional Intake for Fatty Acids. Collective Expert Report [Internet]. Maisons-Alfort. ANSES. 2011. cited 2020 April 5. Available from: https://www.anses.fr/en/system/files/NUT2006sa0359Ra.pdf

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    An adequate intake for EPA + DHA was established for adults at 250 mg/day.

    “An adequate intake for EPA + DHA was established for adults at 250 mg/day.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [27] EFSA Panel on Dietetic Products, Nutrition, and Allergies (NDA), 2010, EFSA J

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Long-term supplemental intakes of EPA and DHA combined of up to about 5 g/day do not appear to increase the risk of spontaneous bleeding or bleeding complications, nor do they affect glucose homeostasis, immune function, or lipid peroxidation, provided the oxidative stability of the n-3 LCPUFAs is guaranteed.

    “Long-term supplemental intakes of EPA and DHA combined of up to about 5 g/day do not appear to increase the risk of spontaneous bleeding or bleeding complications, nor do they affect glucose homeostasis, immune function, or lipid peroxidation, provided the oxidative stability of the n-3 LCPUFAs is guaranteed.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [28] EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2012, EFSA J

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    The IOM established adequate intake levels for ALA only as this was considered the only n-3 fatty acid that is nutritionally essential.

    “The Institute of Medicine (IOM) of the National Academies established adequate intake levels for ALA only as this was considered the only n-3 fatty acid that is nutritionally essential [29].”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [29] Institute of Medicine (US), 2005

      Not checked in the free run.

  • Classified as probably not a substantial claim.

    Premisereasoning

    The NHMRC considered it prudent to encourage increased consumption of n-3 LCPUFA (DHA, EPA, and DPA) given evidence and modest intakes currently consumed in Australia and New Zealand.

    “Given this evidence, and the modest intakes currently consumed in Australia and New Zealand, the NHMRC considered it prudent to encourage increased consumption of n-3 LCPUFA (DHA, EPA, and DPA).”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [34] National Health and Medical Research Council (AU), 2017

      Not checked in the free run.

  • Classified as probably not a substantial claim. May combine two claims.

    Premisecitation

    For adult pregnant and lactating females, the minimum intake for optimal adult health and fetal and infant development is 0.3 g/day EPA + DHA, of which at least 0.2 g/day should be DHA.

    “For adult pregnant and lactating females, the minimum intake for optimal adult health and fetal and infant development is 0.3 g/day EPA + DHA, of which at least 0.2 g/day should be DHA.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [26] Food and Agriculture Organization of the United Nations, 2010

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    A 100 mg/day incremental increase in DHA intake was associated with a 14% lower risk of dementia and a 37% lower risk of Alzheimer's disease.

    “Specifically, a 100 mg/day incremental increase in DHA intake was associated with a 14% lower risk of dementia and a 37% lower risk of AD.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [82] Zhang, 2016, Am J Clin Nutr source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    A higher omega-3 index was associated with a greater hippocampal volume in the Women's Health Initiative Memory Study and with a larger brain volume and improved cognitive test scores in the Framingham offspring cohort-based study.

    “A higher omega-3 index was associated with a greater hippocampal volume in the Women's Health Initiative Memory Study [80] and with a larger brain volume and improved cognitive test scores in the Framingham offspring cohort-based study [81].”
    Quote in the paperNot a substantial claim0 of 2 sources checked
    • cites [80] Pottala, 2014, Neurology source

      Not checked in the free run.

    • cites [81] Tan, 2012, Neurology source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Omega-3 supplementation was associated with a reduction in total and fatal myocardial infarction risk by 28% and 50%, respectively.

    “However, the secondary outcomes were highly relevant as omega-3 supplementation was associated with a reduction in total and fatal myocardial infarction risk by 28% and 50%, respectively.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [53] Manson, 2019, N Engl J Med source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    A 26% reduction of cardiovascular death (myocardial infarction or stroke) was reported, while the risk of cardiovascular death or non-fatal myocardial infarction were reduced by 25%.

    “Furthermore, a 26% reduction of cardiovascular death (myocardial infarction or stroke) was reported, while the risk of cardiovascular death or non-fatal myocardial infarction were reduced by 25%.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [54] Bhatt, 2019, N Engl J Med source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Relatively high fish consumption among 5,386 study participants was associated with a 60% lower risk of dementia and a 70% lower risk of Alzheimer's disease over an average of 2.1 years in a population-based prospective study of people aged 55 or older who were free from dementia at baseline.

    “Similarly, relatively high fish consumption among 5,386 study participants was associated with a 60% lower risk of dementia and a 70% lower risk of AD over an average of 2.1 years in a population-based prospective study of people aged 55 or older who were free from dementia at baseline [78].”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [78] Kalmijn, 1997, Ann Neurol source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    An in-depth analysis of the VITAL study results demonstrated an 8% reduction in major cardiovascular events, though not statistically significant.

    “Indeed, while the primary outcome of the study, a reduction in major cardiovascular events (a composite of myocardial infarction, stroke, and death from cardiovascular causes), was not achieved with statistical significance, the analysis did demonstrate an 8% reduction in such events.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [53] Manson, 2019, N Engl J Med source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Lower serum DHA levels are associated with an increase in cerebral amyloidosis in healthy older adults, whereas a high DHA level is associated with preservation of brain volume.

    “Lower serum DHA levels have also been associated with an increase in cerebral amyloidosis (build-up of protein deposits called amyloids) in healthy older adults, whereas a high DHA level has been associated with preservation of brain volume [76].”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [76] Yassine, 2016, JAMA Neurol source

      Not checked in the free run.

  • May combine two claims.

    Interpretationcitation

    n-3 LCPUFA supplementation does not appear to benefit patients with Alzheimer's disease, although it might benefit patients with mild cognitive impairment.

    “Clinical trial results have also suggested that n-3 LCPUFA supplementation does not appear to benefit patients with AD, although it might benefit patients with mild cognitive impairment.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Premisecitation

    In people who do not consume the recommended 1 or 2 servings of fish a week, the n-3 LCPUFA supplementation was linked to a 40% reduction in heart attacks; however, among the subjects who followed the fish consumption recommendation, there was no such association.

    “In people who do not consume the recommended 1 or 2 servings of fish a week, the n-3 LCPUFA supplementation was linked to a 40% reduction in heart attacks; however, among the subjects who followed the fish consumption recommendation, there was no such association.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [53] Manson, 2019, N Engl J Med source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Additional risk reductions included: 31% lower risk of fatal or non-fatal myocardial infarction; 20% lower risk of cardiovascular death; 32% lower risk of hospitalization or unstable angina; and 28% lower risk of fatal or non-fatal stroke.

    “Additional risk reductions included: 1) 31% lower risk of fatal or non-fatal myocardial infarction; 2) 20% lower risk of cardiovascular death; 3) 32% lower risk of hospitalization or unstable angina; and 4) 28% lower risk of fatal or non-fatal stroke.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [54] Bhatt, 2019, N Engl J Med source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S2 (checkable), S3 (load-bearing).

    Interpretationreasoning

    Variations in dietary patterns might reflect the adoption of a healthier lifestyle, adopted in concert with the contribution provided by the single-nutrient supplementation.

    “Furthermore, variations in dietary patterns might reflect the adoption of a healthier lifestyle, adopted in concert with the contribution provided by the single-nutrient supplementation.”
    Quote in the paperNot a substantial claim

  • Classified as probably not a substantial claim.

    Premisecitation

    ANSES concluded that, based on the totality of available data, there is plausible evidence supporting recommendations for a sufficient dietary intake of PUFA, and in particular n-3 LCPUFA for support maintenance in mental health.

    “Moreover, ANSES concluded that, based on the totality of available data, there is plausible evidence supporting recommendations for a sufficient dietary intake of PUFA, and in particular n-3 LCPUFA for support maintenance in mental health.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [38] French Agency for Food, Environmental and Occupational Health Safety (ANSES). Update of the Recommended Nutritional Intake for Fatty Acids. Collective Expert Report [Internet]. Maisons-Alfort. ANSES. 2011. cited 2020 April 5. Available from: https://www.anses.fr/en/system/files/NUT2006sa0359Ra.pdf

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    A 2019 meta-analysis of double-blind randomized placebo-controlled trials (including 26 studies; 2,160 participants) showed an overall beneficial effect of n-3 LCPUFA on depression symptoms, and both EPA-pure (=100% EPA) and EPA-major formulations (≥60% EPA) demonstrated clinical benefits at an EPA dosage of ≤1 g/day.

    “A 2019 meta-analysis of double-blind randomized placebo-controlled trials (including 26 studies; 2,160 participants) showed an overall beneficial effect of n-3 LCPUFA on depression symptoms, and both EPA-pure (= 100% EPA) and EPA-major formulations (≥ 60% EPA) demonstrated clinical benefits at an EPA dosage of ≤ 1 g/day [127].”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [127] Liao, 2019, Transl Psychiatry source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    In that trial, DHA supplementation resulted in longer gestation duration (2.9 day; P = 0.041), greater birth weight (172 g; P = 0.004), birth length (0.7 cm; P = 0.022), and head circumference (0.5 cm; P = 0.012).

    “DHA supplementation also resulted in longer gestation duration (2.9 day; P = 0.041), greater birth weight (172 g; P = 0.004), birth length (0.7 cm; P = 0.022), and head circumference (0.5 cm; P = 0.012).”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [131] Carlson, 2013, Am J Clin Nutr source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S2 (checkable), S3 (load-bearing), S4 (based).

    Interpretationnone given

    Distinct protective mechanisms are likely to be activated.

    “Moreover, distinct protective mechanisms are likely to be activated.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Premisecitation

    The 2015 Cochrane review authors reported a small-to-modest beneficial effect on depressive symptoms, although that effect was not clinically significant.

    “However, those authors did report a small-to-modest beneficial effect on depressive symptoms, although that effect was not clinically significant.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [120] Appleton, 2015, Cochrane Database Syst Rev

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    Major depressive disorder affects one tenth of the world's population and has been reported to be the world's leading cause of disability.

    “Major depressive disorder (MDD) affects one tenth of the world's population and has been reported to be the world's leading cause of disability [9192].”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [9192]

      Not checked in the free run.

  • Classified as probably not a substantial claim. May combine two claims.

    Interpretationreasoning

    Observational studies may disclose preventive effects associated with disease initiation, whereas in randomized trials involving patients already carrying a disease, the outcome more likely presents as a slowing of disease progression or a reduction in disease-related complications.

    “Observational studies may disclose preventive effects associated with disease initiation, whereas in randomized trials involving patients already carrying a disease, the outcome more likely presents as a slowing of disease progression or a reduction in disease-related complications.”
    Quote in the paperSubstantial claim

  • Classified as probably not a substantial claim.

    Premisecitation

    n-3 LCPUFA supplementation may be a valuable and biologically plausible tool in the management of neurodegenerative diseases.

    “Therefore, Avallone and colleagues [90] concluded n-3 LCPUFA supplementation may indeed be a valuable and biologically plausible tool in the management of neurodegenerative diseases.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [90] Avallone, 2019, Int J Mol Sci source

      Not checked in the free run.

    • Rests on an assumption: Treatment with omega-3 fatty acids is generally safe and well-tolerated.

  • May combine two claims.

    Interpretationcitation

    Evidence regarding the effectiveness of n-3 LCPUFA in depression is compelling, but not all results are conclusive.

    “Evidence regarding the effectiveness of n-3 LCPUFA in depression is compelling, but not all results are conclusive.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Premisecitation

    There is growing evidence that n-3 LCPUFA can improve pregnancy outcomes, such as gestation duration, and they are believed to increase infant growth and enhance short- and long-term development of the offspring.

    “More recently interest in the role of n-3 LCPUFA during early life has increased as there is growing evidence that they can improve pregnancy outcomes, such as gestation duration, and because they are also believed to increase infant growth and enhance short- and long-term development of the offspring [129].”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [129] Larqué, 2012, Br J Nutr source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    In that trial, duration of gestation was higher in the DHA group than in the control group (17.59% vs. 13.72%; P = 0.01) and there was a higher mean birth weight (+68 g) and fewer low birth weight infants (3.41% vs. 5.27%; P = 0.03) in the DHA group.

    “Duration of gestation was higher in the DHA group than in the control group (17.59% vs. 13.72%; P = 0.01) and there was a higher mean birth weight (+ 68 g) and fewer low birth weight infants (3.41% vs. 5.27%; P = 0.03) in the DHA group.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [130] Makrides, 2010, JAMA source

      Not checked in the free run.

  • Classified as probably not a substantial claim. May combine two claims.

    Premisecitation

    The protective effects exerted by n-3 LCPUFAs are likely to be modulated by patient-related factors, some of which may have a significant genetic component and may be unmodifiable, and may be unpredictable via routine clinical and biochemical evaluation.

    “Avallone and colleagues [90] stated that the protective effects exerted by n-3 LCPUFAs are likely to be modulated by patient-related factors, some of which may have a significant genetic component and may, therefore, be unmodifiable, and furthermore, may be unpredictable via routine clinical and biochemical evaluation.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [90] Avallone, 2019, Int J Mol Sci source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    In that trial, mean birth weight z scores (corrected for gestational age and sex) did not differ between groups, indicating that group differences in birth size were largely a function of gestational age at birth.

    “However, mean birth weight z scores (corrected for gestational age and sex) did not differ between groups, indicating that group differences in birth size were largely a function of gestational age at birth.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [130] Makrides, 2010, JAMA source

      Not checked in the free run.

  • Classified as probably not a substantial claim. May combine two claims.

    Premisecitation

    ANSES considered that the totality of studies regarding n-3 LCPUFA demonstrate that it is associated with psychopathological processes, and its dietary intakes are capable of influencing those processes.

    “The ANSES considered, in their 2011 report, that the totality of studies regarding n-3 LCPUFA demonstrate that it is associated with psychopathological processes, and its dietary intakes are capable of influencing those processes [38].”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [38] French Agency for Food, Environmental and Occupational Health Safety (ANSES). Update of the Recommended Nutritional Intake for Fatty Acids. Collective Expert Report [Internet]. Maisons-Alfort. ANSES. 2011. cited 2020 April 5. Available from: https://www.anses.fr/en/system/files/NUT2006sa0359Ra.pdf

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Pharmacological treatments with currently available antidepressants, although proven effective in treating moderate to severe symptoms in major depressive disorder, have modest beneficial effects and various adverse effects.

    “Pharmacological treatments with the currently available antidepressants, although proven to be effective in treating moderate to severe symptoms in MDD, have modest beneficial effects and various adverse effects [93].”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [93] Cipriani, 2018, Lancet source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    In that trial, there were no reported adverse effects and no safety concerns were identified in the DHA group.

    “There were no reported adverse effects and no safety concerns were identified in the DHA group.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [131] Carlson, 2013, Am J Clin Nutr source

      Not checked in the free run.

  • Classified as probably not a substantial claim. May combine two claims.

    Interpretationcitation

    In controlled trials, dietary supplementation is usually carried out over a relatively limited time span compared with the life-long exposure of real-life observational studies; thus, a difference in the time courses of the two approaches could play a relevant role.

    “Some of the reasons that may account for the inconsistencies are that, in controlled trials, dietary supplementation is usually carried out over a relatively limited time span compared with the life-long exposure of real-life observational studies; thus, a difference in the time courses of the 2 approaches could play a relevant role.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Premisecitation

    In that trial, the mean DHA intake for the DHA-supplemented group was 469 mg/day, resulting in higher maternal and cord RBC-phospholipid-DHA levels (2.6%; P < 0.001) than those in the placebo group.

    “The mean DHA intake for the DHA-supplemented group was 469 mg/day, resulting in higher maternal and cord RBC-phospholipid-DHA levels (2.6%; P < 0.001) than those in the placebo group.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [131] Carlson, 2013, Am J Clin Nutr source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    Lapillonne highlighted that current nutritional management guidelines may not be suitable for recommending sufficient amounts of preformed DHA.

    “Lapillonne [6] highlighted that current nutritional management guidelines may not be suitable for recommending sufficient amounts of preformed DHA.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [6] Lapillonne, 2014, World Rev Nutr Diet source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    The meta-analysis authors concluded that n-3 LCPUFA supplementation during pregnancy is an effective strategy for reducing the incidence of preterm births; however, it probably increases the incidence of post-term pregnancies.

    “The authors concluded that n-3 LCPUFA supplementation during pregnancy is an effective strategy for reducing the incidence of preterm births; however, it probably increases the incidence of post-term pregnancies.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [5] Middleton, 2018, Cochrane Database Syst Rev

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    The meta-analysis authors detected a possible reduced risk of perinatal death, neonatal care admission, and low birth weight infants as well as a small increased risk of low gestational age infants with n-3 LCPUFA supplementation.

    “Additionally, the authors detected a possible reduced risk of perinatal death, neonatal care admission, and low birth weight infants as well as a small increased risk of low gestational age infants with n-3 LCPUFA supplementation.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [5] Middleton, 2018, Cochrane Database Syst Rev

      Not checked in the free run.

  • Classified as probably not a substantial claim.

    Interpretationnone given

    This novel approach to infant formula composition has given rise to concern and controversy because there is no accountable evidence source for the standards' suitability and safety in healthy infants.

    “This novel approach to infant formula composition has given rise to concern and controversy because there is no accountable evidence source for the standards' suitability and safety in healthy infants.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    A recent overview of the lipid requirements of preterm infants emphasizes the importance of an adequate dietary intake of n-3 LCPUFA to support normal development of preterm infants.

    “A recent overview of the lipid requirements of preterm infants emphasizes the importance of an adequate dietary intake of n-3 LCPUFA to support normal development of preterm infants [6].”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [6] Lapillonne, 2014, World Rev Nutr Diet source

      Not checked in the free run.

68 of 68

  • The paper relies on this without support.

    Less than 20% of the world's human population consume ≥ 250 mg/day of seafood-origin n-3 LCPUFA.

    “Global dietary intakes of n-3 LCPUFA has been examined, and it has been estimated that less than 20% of the world's human population consume ≥ 250 mg/day of seafood-origin n-3 LCPUFA.”

  • The paper relies on this without support.

    The current mean intakes of EPA and DHA in the United States are approximately 100 mg/day.

    “This recommendation is similar to the current mean intakes of EPA and DHA in the United States (US) (approximately 100 mg/day), an intake that is much lower than that being recommended by many groups worldwide.”

  • The paper relies on this without support.

    n-3 LCPUFA are involved in many physiological and metabolic processes and play a key role in human metabolism.

    “The n-3 LCPUFA are involved in many physiological and metabolic processes and hence play a key role in human metabolism.”

  • The paper relies on this without support.

    ALA is essential in human nutrition as a precursor for n-3 LCPUFA.

    “ALA is essential in human nutrition as a precursor for n-3 LCPUFA.”

  • The paper relies on this without support.

    Fish, in particular fatty fish, is a rich source of n-3 LCPUFA (EPA and DHA).

    “Fish, in particular fatty fish, is a rich source of n-3 LCPUFA (EPA and DHA).”

  • The paper relies on this without support.

    The developing brain accumulates large amounts of DHA both pre- and postnatally, particularly during the first 2 years of life, with DHA predominantly acquired from the mother via placental transfer and breast milk.

    “The developing brain accumulates large amounts of DHA both pre- and postnatally, particularly during the first 2 years of life, with DHA predominantly acquired from the mother via placental transfer and breast milk.”

  • The paper relies on this without support.

    The conversion of ALA into EPA and DHA is decreased when the amount of LA in the diet increases (and vice versa).

    “The conversion of ALA into EPA and DHA is decreased when the amount of LA in the diet increases (and vice versa).”

  • The paper relies on this without support.

    DHA is a key/essential component of membrane structural lipids/phospholipids in the brain, nervous tissue, and retina.

    “The key role of n-3 LCPUFA has been associated specifically with DHA as it is a key component of membrane structural lipids, especially in nervous tissue and the retina.”
    “Because DHA is an essential component of cellular membrane phospholipids in the brain, researchers have hypothesized that n-3 LCPUFAs might protect cognitive function by helping to maintain neuronal function and cell membrane integrity within the brain [73].”

  • The paper relies on this without support.

    The developing brain accumulates large amounts of DHA both pre- and postnatally, particularly during the first 2 years of life.

    “The developing brain accumulates large amounts of DHA both pre- and postnatally, particularly during the first 2 years of life.”

  • The paper relies on this without support.

    Treatment with omega-3 fatty acids is generally safe and well-tolerated.

    “Regardless, treatment with omega-3 fatty acids is generally reported to be safe and well-tolerated.”

  • The paper relies on this without support.

    Major depressive disorder is of heterogeneous etiology with multiple contributory biological mechanisms.

    “MDD is of heterogeneous etiology with multiple contributory biological mechanisms.”
11 of 11

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Arachidonic acid, EPA, and DHA are essential fatty acids required for neurological development, especially in neonates, and play a crucial role in maintaining a healthy immune system.

    “Arachidonic acid, AA (20:4 D 5,8,11,14 ), eicosapentaenoic acid, EPA (20:5 D 5,8,11,14,17 ), and docosahexaenoic acid, DHA (22:6 D 5,8,11,14,17,19 ), are essential fatty acids required for neurological development, especially in neonates, and play a crucial role in maintaining a healthy immune system [58].”

    From Key Targets for Improving Algal Biofuel Production (2021) · cites this paper as [58]

    The ‘Brain health and cognitive functionality’ section links long-chain fatty acids, particularly DHA, to early brain development and reports that intake during pregnancy and early life may affect later neurological and immune function. The ‘Metabolism’ section identifies ALA as essential and describes EPA and DHA as synthesized from it; the paper does not establish that all three named fatty acids are essential or crucial to maintaining a healthy immune system. Page numbers were not available in our copy. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

  • Two different cardiovascular-death risk reductions are reported for REDUCE-IT

    Minor

    The same REDUCE-IT results paragraph reports a 26% reduction in cardiovascular death and later a 20% lower risk of cardiovascular death, without distinguishing the endpoints.

1 of 1

Cites

Flagged first, then by citations

Research works printed but not linked: 12

  1. Middleton, 2018, Cochrane Database Syst Rev, 11, CD003402
  2. Kinsella, 1990, Nutrition, 6, 24
  3. Food and Agriculture Organization of the United Nations, 2010, FAO Fats and Fatty Acids in Human Nutrition. Report of an Expert Consultation
  4. EFSA Panel on Dietetic Products, Nutrition, and Allergies (NDA), 2010, EFSA J, 8, 1461
  5. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2012, EFSA J, 10, 2815
  6. US Department of Agriculture, 2015, Scientific Report of the 2015 Dietary Guidelines Advisory Committee
  7. National Health and Medical Research Council (AU), 2017, Nutrient Reference Values for Australia and New Zealand including Recommended Dietary Intakes (version 1.2)
  8. Beaufrère, 2001, Recommended Nutritional Intakes for the French Population
  9. Abdelhamid, 2018, Cochrane Database Syst Rev, 7, CD003177
  10. Burckhardt, 2016, Cochrane Database Syst Rev, 4, CD009002
  11. Sydenham, 2012, Cochrane Database Syst Rev, 6, CD005379
  12. Appleton, 2015, Cochrane Database Syst Rev, 2015, CD004692

Cited by

Sorted by citations

Related

Authors
Van Dael, P.
Affiliations
Nutrition Science & Advocacy, DSM Nutritional Products, 4303 Kaiseraugst, Switzerland.
ORCID
Van Dael, Peter
Venue
Nutrition Research and Practice
Publisher
XMLink
Published
2021
Volume
15
Issue
2
Pages
137
ISSN
  • 1976-1457 (ISSN-L)
  • 2005-6168
DOI
10.4162/nrp.2021.15.2.137
PMC
PMC8007408
OpenAlex
W3118775982
Semantic Scholar
8dbeea342270caea041bd8207e7a189a3f6a9d53
Cited by
138
References
128
Citations by year
2026: 30 · 2025: 30 · 2024: 36 · 2023: 16 · 2022: 18 · 2021: 8
FWCI
2.60
Type
journal article
Language
en
Open access
Licence
Locations
  • Nutrition Research and Practice (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Life Sciences › Agricultural and Biological Sciences › Aquatic Science › Aquaculture Nutrition and Growth
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Nutritional Studies and Diet
Keywords
n-3 long-chain polyunsaturated fatty acids, docosahexaenoic acid, eicosapentaenoic acid, dietary recommendations, cardiovascular disease, neurodegenerative diseases, depression, preterm birth, infant formula, arachidonic acid, fatty acid metabolism, fish consumption

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-09.

Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-09.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review